biphasic insulin aspart 50

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients